Showing results (1461-1470 of 1,814) with videos related to
Sort By:
Pageof 182
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 19, 2021
European Society of Gynaecological Oncology guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking surgeryChristina Fotopoulou, François Planchamp, Tugce Aytulu, et al.Allergy, Asthma & Immunology Research|January 8, 2016
Defining Chronic Cough: A Systematic Review of the Epidemiological LiteratureWoo Jung Song, Yoon Seok Chang, Shoaib Faruqi, et al.Journal of the American College of Cardiology|December 4, 2024
Major Bleeding and Mortality After Revascularization of Left Main DiseaseGennaro Giustino, Joseph F Sabik, Patrick W Serruys, et al.JACC. Cardiovascular Interventions|February 7, 2025
Randomized Trial of Biolimus DCB for In-Stent Restenosis: The Primary Results of the REFORM StudyRobert A Byrne, Joo-Yong Hahn, Peter O'Kane, et al.Cardiovascular Revascularization Medicine : Including Molecular Interventions|June 16, 2023
Design and rationale of a prospective, randomized, non-inferiority trial to determine the safety and efficacy of the Biolimus A9™ drug coated balloon for the treatment of in-stent restenosis: First-in-man trial (REFORM)Bryan P Traynor, Sean Fitzgerald, Fernando Alfonso, et al.Journal of the National Cancer Institute|February 6, 2003
Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trialJonathan M Kurie, Reuben Lotan, J Jack Lee, et al.Cardiovascular Revascularization Medicine : Including Molecular Interventions|June 3, 2019
Absorb Bioresorbable Scaffold Versus Xience Metallic Stent for Prevention of Restenosis Following Percutaneous Coronary Intervention in Patients at High Risk of Restenosis: Rationale and Design of the COMPARE ABSORB TrialChun Chin Chang, Yoshinobu Onuma, Stephan Achenbach, et al.ACS Medicinal Chemistry Letters|May 18, 2019
Discovery of BNC375, a Potent, Selective, and Orally Available Type I Positive Allosteric Modulator of α7 nAChRsAndrew J Harvey, Thomas D Avery, Laurent Schaeffer, et al.Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|August 17, 2018
Radial versus femoral artery access in patients undergoing PCI for left main coronary artery disease: analysis from the EXCEL trialShmuel Chen, Björn Redfors, Yangbo Liu, et al.The British Journal of Ophthalmology|November 26, 2018
Mild form of oculocutaneous albinism type 1: phenotypic analysis of compound heterozygous patients with the R402Q variant of the TYR geneSolene Monfermé, Eulalie Lasseaux, Catherine Duncombe-Poulet, et al.Pageof 182